NantKwest Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
2,047.00
6,185.00
236,876.00
120,809.00
96,423.00
96,226
Depreciation, Depletion & Amortization
4.00
36.00
1,472.00
3,607.00
5,566.00
9,555
Other Funds
-
-
2,415.00
1,106.00
1,039.00
24,342
Funds from Operations
1,524.00
4,625.00
25,587.00
42,435.00
52,008.00
62,827
Changes in Working Capital
856.00
793.00
282.00
3,842.00
3,228.00
554
Net Operating Cash Flow
668.00
5,418.00
25,305.00
38,593.00
48,780.00
63,381
Capital Expenditures
3.00
235.00
2,241.00
6,560.00
34,815.00
Purchase/Sale of Investments
-
-
171,165.00
107,112.00
134,367.00
Net Investing Cash Flow
3.00
235.00
175,224.00
113,672.00
99,552.00
Issuance/Reduction of Debt, Net
1.00
53.00
132.00
32.00
19,932.00
Net Financing Cash Flow
905.00
64,407.00
317,333.00
15,560.00
34,983.00
Net Change in Cash
234.00
58,754.00
116,804.00
167,825.00
15,789.00
Free Cash Flow
671.00
5,653.00
27,546.00
45,153.00
83,595.00
Deferred Taxes & Investment Tax Credit
-
-
302.00
575.00
497.00
498
Net Assets from Acquisitions
-
-
1,818.00
-
-
Change in Capital Stock
906.00
64,460.00
319,880.00
14,422.00
14,012.00

About NantKwest

View Profile
Address
3530 John Hopkins Court
San Diego California 92121
United States
Employees -
Website http://www.nantkwest.com
Updated 07/08/2019
NantKwest, Inc. engages in the development of immunotherapies with a focus on harnessing the power of the innate immune system. It uses natural killer cells to treat cancer, infectious diseases, and inflammatory diseases. The firm operates through the following geographical segments: United States; Europe; and Other Non-U.